Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.840
+0.090 (1.89%)
Nov 5, 2024, 4:00 PM EST - Market closed
Elicio Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
52.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortress Biotech | 82.62M |
Aadi Bioscience | 23.82M |
SCYNEXIS | 9.67M |
Affimed | 7.96M |
Kezar Life Sciences | 7.00M |
Lucid Diagnostics | 3.80M |
OncoCyte | 1.02M |
ELTX News
- 5 days ago - Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - GlobeNewsWire
- 20 days ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 7 weeks ago - Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - GlobeNewsWire
- 2 months ago - Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - GlobeNewsWire